Publications by authors named "M Natsumeda"
Introduction: Leptomeningeal disease (LMD) in diffuse midline gliomas (DMGs) can lead to devastating symptoms such as severe pain, urinary incontinence, and tetraparesis, with limited treatment options. We determined whether detecting H3F3A K27M-mutant droplets in cerebrospinal fluid (CSF) circulating tumor deoxyribonucleic acid (ctDNA) could be a biomarker for detecting LMD in DMGs.
Methods: Twenty-five CSF samples were obtained from 22 DMG patients.
Article Synopsis
- The EF-14 clinical trial confirmed the safety and efficacy of tumor-treating fields (TTFields) in glioblastoma, prompting this study to assess its status among Japanese patients meeting the same criteria.
- A multicenter retrospective analysis was conducted with data from 607 patients, ultimately focusing on 537, where 39% received TTField treatment, highlighting factors like younger age and having a caregiver as key determinants for usage.
- Results showed that despite high compliance rates (over 75%) and a median usage duration of 11 months, TTFields did not significantly impact progression-free survival or overall survival in patients with glioblastoma.
Article Synopsis
- Brain arteriovenous malformations (bAVMs) are complex vascular anomalies that can cause strokes in young adults, and current surgical treatments are too invasive.
- Recent research has discovered that mutations in the KRAS gene in brain endothelial cells are linked to bAVMs, but how these malformations develop postnatally is still unclear.
- A new mouse model showed that introducing mutant KRAS in specific brain cells results in bAVMs, revealing the underlying mechanisms and suggesting that CRISPR technology can effectively suppress the development of these malformations.
Background: To improve the outcome in newly diagnosed glioblastoma patients with maximal resection, we aimed to evaluate the efficacy and safety of implantation of carmustine wafers (CWs), radiation concomitant with temozolomide and bevacizumab, and maintenance chemotherapy with six cycles of temozolomide and bevacizumab.
Method: This prospective phase II study enrolled glioblastoma patients considered candidates for complete resection (> 90%) of a contrast-enhanced lesion. The CWs were intraoperatively implanted into the resection cavity after achieving maximal resection.
Background: A previous Phase II clinical trial, conducted from 1995 to 2003, evaluated CNS germ cell tumors (GCTs) using a three-group treatment stratification based on histopathology. The primary objective of the study was to assess the long-term efficacy of standardized treatment regimens, while the secondary objective focused on identifying associated long-term complications.
Methods: Total 228 patients were classified into three groups for treatment: germinoma (n=161), intermediate prognosis (n=38), and poor prognosis (n=28), excluding one mature teratoma case.